Skip to main content

Davern Capital Partners, LP

SEC CIK
0002003147
Latest filing
Aug 13, 2026

The latest 13F from Davern Capital Partners, LP covers Q2 2026 (filed Aug 13, 2026): 15 long positions worth $586.5M. The top 10 holdings make up 86.8% of the portfolio, and the largest is BioNTech SE (BNTX) at 12.0%. Livermore has 3 filings on Form 13F from this institution, going back to Q4 2025.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
3
Est. +$64.1M
Added
10
Est. +$254.5M
Reduced
2
Est. −$10.3M
Sold out
5
Est. −$110.1M

Top 5 holdings

Share of this quarter's portfolio value

  1. BNTXBioNTech SE
    12.0%$70.2MHistory
  2. ROIVRoivant Sciences Ltd.
    11.7%$68.4MHistory
  3. RPRXRoyalty Pharma plc
    11.0%$64.8MHistory
  4. IONSIonis Pharmaceuticals Inc
    10.8%$63.3MHistory
  5. INSMINSMED Inc
    10.2%$59.7MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. BNTXBioNTech SE
    +$41.8MAddedHistory
  2. INSMINSMED Inc
    +$40.2MAddedHistory
  3. ROIVRoivant Sciences Ltd.
    +$37.5MAddedHistory
  4. RPRXRoyalty Pharma plc
    +$35.6MAddedHistory
  5. ALNYAlnylam Pharmaceuticals, Inc.
    +$34.0MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. ALNYAlnylam Pharmaceuticals, Inc.
    +5.80 pp0.0% → 5.8%History
  2. ROIVRoivant Sciences Ltd.
    +5.03 pp6.6% → 11.7%History
  3. BNTXBioNTech SE
    +4.53 pp7.4% → 12.0%History
  4. RPRXRoyalty Pharma plc
    +4.21 pp6.8% → 11.0%History
  5. VERAVera Therapeutics, Inc.
    +3.65 pp0.0% → 3.6%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. PFEPfizer Inc
    −$44.8MSold outHistory
  2. ARGXArgenx SE
    −$25.6MSold outHistory
  3. LLYEli Lilly & Co
    −$25.1MSold outHistory
  4. ABVXAbivax S.A.
    −$8.70MSold outHistory
  5. NTRANatera, Inc.
    −$6.78MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. PFEPfizer Inc
    −12.28 pp12.3% → 0.0%History
  2. ARGXArgenx SE
    −7.02 pp7.0% → 0.0%History
  3. LLYEli Lilly & Co
    −6.88 pp6.9% → 0.0%History
  4. NTRANatera, Inc.
    −2.39 pp7.9% → 5.5%History
  5. ABVXAbivax S.A.
    −2.39 pp2.4% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$586.5M
+$222.0M (+60.9%) vs. prior quarter
Positions
15
−2 vs. prior quarter
Top 10 concentration
86.8%
Top 10 as share of value
Turnover
25.3%
Q2 2026, one quarter
Average holding period
2.6 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2025), so positions held before then are understated.

13F filings by quarter

3 quarters, going back to Q4 2025. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $586.5M (Q2 2026)

Q4 2025: $309.3MQ1 2026: $364.5MQ2 2026: $586.5M
Q4 2025Q2 2026
13F filings of Davern Capital Partners, LP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 13, 202615$586.5MBNTXROIVRPRXvs. Q1 2026SEC
Q1 2026May 14, 202617$364.5MPFEREGNINSMvs. Q4 2025SEC
Q4 2025Feb 13, 202614$309.3MPFEREGNBNTX–SEC